BridgeBio Oncology (NASDAQ: BBOT) reports new RAS and PI3Kα clinical data

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. reported that it issued a press release sharing new clinical data for three innovative and differentiated RAS and PI3Kα pipeline programs.

The press release, dated January 7, 2026 and titled “BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs,” is attached as an exhibit to this current report, with the full scientific and clinical details contained in that separate document.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001869105 0001869105 2026-01-07 2026-01-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

BridgeBio Oncology Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41955		39-3690783
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

256 E. Grand Avenue, Suite 104

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 405-4770

(Telephone number, including area code, of agent for service)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		BBOT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 7, 2026, BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release titled “BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release dated January 7, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
Date: January 7, 2026				By:		/s/ Eli Wallace
				Name:		Eli Wallace
				Title:		Chief Executive Officer

FAQ

What did BridgeBio Oncology Therapeutics (BBOT) disclose in this 8-K?

BridgeBio Oncology Therapeutics disclosed that it issued a press release providing new clinical data for three innovative and differentiated RAS and PI3Kα pipeline programs.

When was the new BridgeBio Oncology Therapeutics clinical data press release issued?

The press release titled “BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs” was dated January 7, 2026.

How many BridgeBio Oncology Therapeutics programs are covered in the new clinical data update?

The press release discussed in the report covers clinical data for three RAS and PI3Kα pipeline programs at BridgeBio Oncology Therapeutics.

Where can investors find the detailed BridgeBio Oncology Therapeutics clinical data mentioned in the 8-K?

The detailed clinical data are contained in the press release, which is attached as Exhibit 99.1 to the report and incorporated by reference.

What exhibit number contains the BridgeBio Oncology Therapeutics press release with new clinical data?

The press release containing the new clinical data for the three RAS and PI3Kα programs is filed as Exhibit 99.1.